Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioLineRx Ltd.BLRX · Entity 7843 | Director | March 18, 2026 | March 30, 2026 |
| Protalix BioTherapeutics, Inc.PLX · Entity 2671 | Director | September 03, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioLineRx Ltd.
Report date March 18, 2026 · Filed March 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, 0.1 NIS per shareSEC Table I · non-derivative | Direct | 3,705,000 |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 3,705,000 |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.84 · Expires 2026-07-05 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Options granted under the 2003 Amended and Restated Share Incentive Plan. F2: The grant date of this grant is July 5, 2016. This option grant is fully vested as of this date. F12: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.92 · Expires 2027-07-05 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F1: Options granted under the 2003 Amended and Restated Share Incentive Plan. F3: The grant date of this grant is July 5, 2017. This option grant is fully vested as of this date. F12: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.89 · Expires 2028-07-05 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F1: Options granted under the 2003 Amended and Restated Share Incentive Plan. F4: The grant date of this grant is July 5, 2018. This option grant is fully vested as of this date. F12: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2029-07-02 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance Not disclosed F1: Options granted under the 2003 Amended and Restated Share Incentive Plan. F5: The grant date of this grant is July 2, 2019. This option grant is fully vested as of this date. F12: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.37 · Expires 2030-07-02 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance Not disclosed F1: Options granted under the 2003 Amended and Restated Share Incentive Plan. F6: The grant date of this grant is July 2, 2020. This option grant is fully vested as of this date. F12: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.39 · Expires 2031-07-02 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance Not disclosed F1: Options granted under the 2003 Amended and Restated Share Incentive Plan. F7: The grant date of this grant is July 2, 2021. This option grant is fully vested as of this date. F12: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.09 · Expires 2032-07-03 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance Not disclosed F1: Options granted under the 2003 Amended and Restated Share Incentive Plan. F8: The grant date of this grant is July 3, 2022. This option grant is fully vested as of this date. F12: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.08 · Expires 2033-07-03 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance Not disclosed F1: Options granted under the 2003 Amended and Restated Share Incentive Plan. F9: The grant date of this grant is July 3, 2023. This option grant is fully vested as of this date. F12: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.09 · Expires 2032-07-03 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance Not disclosed F1: Options granted under the 2003 Amended and Restated Share Incentive Plan. F10: The grant date of this grant is July 3, 2024. This option grant is fully vested as of this date. F12: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.05 · Expires 2034-08-14 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · Balance Not disclosed F1: Options granted under the 2003 Amended and Restated Share Incentive Plan. F11: The grant date of this grant is October 1, 2024. As of this date, 856,200 of the options were vested as of the date of appointment. The remaining 1,198,800 options will vest in 7 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date. F12: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Options granted under the 2003 Amended and Restated Share Incentive Plan.
F2: The grant date of this grant is July 5, 2016. This option grant is fully vested as of this date.
F3: The grant date of this grant is July 5, 2017. This option grant is fully vested as of this date.
F4: The grant date of this grant is July 5, 2018. This option grant is fully vested as of this date.
F5: The grant date of this grant is July 2, 2019. This option grant is fully vested as of this date.
F6: The grant date of this grant is July 2, 2020. This option grant is fully vested as of this date.
F7: The grant date of this grant is July 2, 2021. This option grant is fully vested as of this date.
F8: The grant date of this grant is July 3, 2022. This option grant is fully vested as of this date.
F9: The grant date of this grant is July 3, 2023. This option grant is fully vested as of this date.
F10: The grant date of this grant is July 3, 2024. This option grant is fully vested as of this date.
F11: The grant date of this grant is October 1, 2024. As of this date, 856,200 of the options were vested as of the date of appointment. The remaining 1,198,800 options will vest in 7 equal quarterly installments, subject to the Reporting Person's continued service to the Issuer as of each vesting date.
F12: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the 2003 Amended and Restated Share Incentive Plan must be registered in the name of a trustee.
Protalix BioTherapeutics, Inc.
Report date September 03, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.59 · Expires 2036-09-03 | Direct | 17,000 |
Reported balance
After 2026-09-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-03 · Grant · Acquired 17,000 · Balance 17,000 F1: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant. F2: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033 and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,500 |
Reported balance
After 2026-09-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-09-03 · Grant · Acquired 8,500 · Balance 8,500 F3: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock. F4: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.
F2: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033 and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.
F3: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.
F4: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Foamix Pharmaceuticals Ltd.
Report date March 09, 2020 · Filed March 11, 2020
Section 16 reporting ended · disclosed 2020-03-11. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 1
1 source rowRow 1 · 2020-03-09 · Disposition to issuer · Disposed 112,200 · Balance 0 F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $11.87 · Expires 2025-06-22 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-03-09 · Disposition to issuer · Disposed 24,000 · Balance 0 F4: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F3: The Options vested over a period of three years from June 22, 2015 (33.3% on each anniversary of such date). |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $4.69 · Expires 2027-07-13 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-03-09 · Disposition to issuer · Disposed 21,435 · Balance 0 F4: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F5: The ordinary shares underlying this option vest over a period of four years (25% on July 13, 2017 and 6.25% every three months thereafter) ending July 13, 2021. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $5.02 · Expires 2028-05-08 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-03-09 · Disposition to issuer · Disposed 24,883 · Balance 0 F4: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F6: The ordinary shares underlying these options vested over a 12 month period, in equal, quarterly installments, ending May 8, 2019. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.66 · Expires 2029-05-16 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-03-09 · Disposition to issuer · Disposed 49,412 · Balance 0 F4: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F7: The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020. |
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $3.53 · Expires 2030-02-27 | Direct | 0 |
Reported balance
After 2020-03-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-03-09 · Disposition to issuer · Disposed 38,156 · Balance 0 F4: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F8: The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending February 27, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2)
F2: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement.
F3: The Options vested over a period of three years from June 22, 2015 (33.3% on each anniversary of such date).
F4: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options.
F5: The ordinary shares underlying this option vest over a period of four years (25% on July 13, 2017 and 6.25% every three months thereafter) ending July 13, 2021.
F6: The ordinary shares underlying these options vested over a 12 month period, in equal, quarterly installments, ending May 8, 2019.
F7: The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020.
F8: The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending February 27, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2026 Filed Sep 9, 2026 21:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantRestricted Stock Units · Derivative | 8,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001178913-26-004471 · ownership.xml · derivative · entry 2 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,500 Underlying: Common Stock · 8,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock. F4 · derivative.exercise_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant. F4 · derivative.expiration_date: The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant. Read SEC document |
| September 03, 2026 Filed Sep 9, 2026 21:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $2.59 | $0.00 |
DisclosureSEC source: 0001178913-26-004471 · ownership.xml · derivative · entry 1 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2036-09-03 F1 · derivative.exercise_date: The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant. F2 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033 and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 21:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $1.64 | $0.00 |
DisclosureSEC source: 0001415889-25-023704 · form4-09042025_050909.xml · derivative · entry 3 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2035-09-03 F3 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. F4 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032 and (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033. Read SEC document |
| September 03, 2025 Filed Sep 4, 2025 21:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantCommon Stock | 7,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-023704 · form4-09042025_050909.xml · nonDerivative · entry 1 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 7,500 F1 · price: Represents restricted shares of common stock awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended (the "Plan"). The restricted shares vest in 12 equal quarterly installments commencing upon the date of grant. F2 · ownership.nature: To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under the Plan must be registered in the name of a trustee. Read SEC document |
| June 10, 2025 Filed Aug 12, 2025 20:30 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | PurchaseCommon Stock | 129,000 | $1.60 | $205,884.00 |
DisclosureSEC source: 0001415889-25-021494 · form4-08122025_040801.xml · nonDerivative · entry 1 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.60 to $1.575 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 21:00 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Option (Right to Buy) · Derivative | 61,676 | $0.00 Strike: $1.66 | $0.00 |
DisclosureSEC source: 0001415889-23-013900 · form4-10032023_051021.xml · derivative · entry 1 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,676 Underlying: Common Stock · 61,676 shares Expires 2033-09-29 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 12 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended. F2 · balance_after: Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030 and (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 22:08 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | PurchaseCommon Stock | 110,000 | $1.42 | $155,815.00 |
DisclosureSEC source: 0001104659-23-001495 · tm232297-1_4seq1.xml · nonDerivative · entry 1 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $1.430 to $1.405 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 07, 2022 Filed Sep 9, 2022 21:02 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001104659-22-098948 · tm2225460-5_4seq1.xml · derivative · entry 1 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-09-07 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., Amended and Restated 2006 Stock Incentive Plan, as amended. F2 · balance_after: Does not include options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030. Read SEC document |
| April 07, 2020 Filed Apr 13, 2020 20:05 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | PurchaseCommon Stock | 64,000 | $2.43 | $155,264.00 |
DisclosureSEC source: 0001104659-20-045926 · tm2015785d1_4.xml · nonDerivative · entry 1 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,000 F1 · price: This transaction was executed in multiple trades at prices ranging from $2.39 to $2.53. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:40 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 38,156 | Not disclosed Strike: $3.53 | Not disclosed |
DisclosureSEC source: 0001209191-20-018199 · doc4.xml · derivative · entry 6 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 38,156 shares Expires 2030-02-27 F4 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F8 · derivative.exercise_date: The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending February 27, 2021. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:40 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 49,412 | Not disclosed Strike: $2.66 | Not disclosed |
DisclosureSEC source: 0001209191-20-018199 · doc4.xml · derivative · entry 5 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 49,412 shares Expires 2029-05-16 F4 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F7 · derivative.exercise_date: The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:40 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 24,883 | Not disclosed Strike: $5.02 | Not disclosed |
DisclosureSEC source: 0001209191-20-018199 · doc4.xml · derivative · entry 4 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 24,883 shares Expires 2028-05-08 F4 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F6 · derivative.exercise_date: The ordinary shares underlying these options vested over a 12 month period, in equal, quarterly installments, ending May 8, 2019. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:40 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 21,435 | Not disclosed Strike: $4.69 | Not disclosed |
DisclosureSEC source: 0001209191-20-018199 · doc4.xml · derivative · entry 3 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 21,435 shares Expires 2027-07-13 F4 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F5 · derivative.exercise_date: The ordinary shares underlying this option vest over a period of four years (25% on July 13, 2017 and 6.25% every three months thereafter) ending July 13, 2021. Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:40 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOptions · Derivative | 24,000 | Not disclosed Strike: $11.87 | Not disclosed |
DisclosureSEC source: 0001209191-20-018199 · doc4.xml · derivative · entry 2 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 24,000 shares Expires 2025-06-22 F4 · price: At the Effective Time, each option to purchase a Foamix Share (a "Foamix Option") was converted into an option to purchase Menlo Common Stock (an "Adjusted Option") with the same terms and conditions as applied to the Foamix Option immediately prior to the Effective Time; however, the Adjusted Option covers a number of shares of Menlo Common Stock equal to the product of (i) the number of Foamix Shares subject to the Foamix Option immediately prior to the Effective Time and (ii) the Exchange Ratio, and has an exercise price per share equal to the quotient of (i) the exercise price per Foamix Share subject to such Foamix Option immediately prior to the Effective Time divided by (ii) the Exchange Ratio. If the CSRs become convertible, then the Menlo board of directors will make equitable adjustments to the exercise price per share of and the number of shares of Menlo Common Stock that are subject to Adjusted Options. F3 · derivative.exercise_date: The Options vested over a period of three years from June 22, 2015 (33.3% on each anniversary of such date). Read SEC document |
| March 09, 2020 Filed Mar 11, 2020 17:40 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | Disposition to issuerOrdinary Shares | 112,200 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-018199 · doc4.xml · nonDerivative · entry 1 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: On March 9, 2020 (the "Closing Date"), pursuant to the Agreement and Plan of Merger, dated as of November 10, 2019, as amended on December 4, 2019 (as amended, the "Merger Agreement"), by and among Menlo Therapeutics Inc., a Delaware corporation ("Menlo"), Foamix Pharmaceuticals Ltd., a company organized under the laws of Israel ("Foamix"), and Giants Merger Subsidiary Ltd., a direct, wholly owned subsidiary of Menlo ("Merger Sub"), Merger Sub merged with and into Foamix, with Foamix surviving as a wholly owned subsidiary of Menlo (the "Merger"). At the effective time of the Merger (the "Effective Time"), each ordinary share, par value NIS 0.16 per share, of Foamix ("Foamix Shares") issued and outstanding immediately prior to the Effective Time was deemed transferred under Israeli law to Menlo in exchange for the right to receive (i) 0.5924 shares (the "Exchange Ratio") of common stock of Menlo ("Menlo Common Stock") and (ii) one contingent stock right (continued in footnote 2) F2 · price: (a "CSR"; and collectively, the "CSRs") which are subject to the terms and conditions of the contingent stock rights agreement, dated as of March 9, 2020, by and between American Stock Transfer & Trust Company, LLC and Menlo (the "CSR Agreement"), as further described in that Current Report on Form 8-K filed by Menlo with the Securities and Exchange Commission on March 9, 2020 (collectively, the "Merger Consideration"). The closing price of a share of Menlo Common Stock on March 6, 2020, the last trading day before the Effective Time, was $4.15. No fractional share of Menlo Common Stock was issued in the Merger, and Foamix shareholders received cash in lieu of fractional shares, as specified in the Merger Agreement. Read SEC document |
| February 27, 2020 Filed Mar 3, 2020 16:33 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOptions · Derivative | 38,156 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-20-015201 · doc4.xml · derivative · entry 1 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,156 Underlying: Ordinary Shares · 38,156 shares Expires 2030-02-27 F1 · security: Each option represents a contingent right to purchase one ordinary share of the issuer. F2 · derivative.exercise_date: The ordinary shares underlying this option award vest over a 12 month period, in equal, quarterly installments, ending February 27, 2021. Read SEC document |
| January 20, 2020 Filed Jan 22, 2020 22:02 UTC | Protalix BioTherapeutics, Inc. PLX · Entity 2671 | GrantStock Options (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.55 | $0.00 |
DisclosureSEC source: 0001104659-20-005970 · tm205452-4_4.xml · derivative · entry 1 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-01-20 F1 · derivative.exercise_date: The shares of common stock underlying the stock options shall vest in 16 equal quarterly installments commencing upon the date of grant. The stock options are subject to accelerated vesting upon a corporate transaction or a change in control as described in the Protalix BioTherapeutics, Inc., 2006 Stock Incentive Plan, as amended. Read SEC document |
| May 16, 2019 Filed May 20, 2019 18:36 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOptions · Derivative | 49,412 | $0.00 Strike: $2.66 | $0.00 |
DisclosureSEC source: 0001209191-19-031532 · doc4.xml · derivative · entry 1 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,412 Underlying: Ordinary Shares · 49,412 shares Expires 2029-05-16 F1 · security: Each option represents a contingent right to purchase one ordinary share of the issuer. F2 · derivative.exercise_date: The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 16, 2020. Read SEC document |
| November 28, 2018 Filed Dec 6, 2018 06:09 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | PurchaseOrdinary Shares | 12,200 | $3.88 | $47,372.60 |
DisclosureSEC source: 0001178913-18-003093 · zk1822353.xml · nonDerivative · entry 3 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,200 Read SEC document |
| November 27, 2018 Filed Dec 6, 2018 06:09 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | PurchaseOrdinary Shares | 50,000 | $3.92 | $195,800.00 |
DisclosureSEC source: 0001178913-18-003093 · zk1822353.xml · nonDerivative · entry 2 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Read SEC document |
| November 26, 2018 Filed Dec 6, 2018 06:09 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | PurchaseOrdinary Shares | 50,000 | $3.89 | $194,600.00 |
DisclosureSEC source: 0001178913-18-003093 · zk1822353.xml · nonDerivative · entry 1 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Read SEC document |
| May 08, 2018 Filed May 10, 2018 17:24 UTC | Foamix Pharmaceuticals Ltd. FOMX · Entity 150527 | GrantOptions · Derivative | 24,883 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001178913-18-001594 · zk1821659.xml · derivative · entry 1 Schwartz Aharon · CIK 0001625184 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,883 Underlying: Ordinary Shares · 24,883 shares Expires 2028-05-08 F1 · security: Each option represents a contingent right to purchase one ordinary share of the issuer. F2 · derivative.exercise_date: The ordinary shares underlying these options vest over a 12 month period, in equal, quarterly installments, ending May 8, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.